Skip to content
ClinCalc Pro
Menu
Osmotic agent / ICP reduction

Hypertonic Saline 3%

Brand names: NaCl 3% Infusion

Used in: Head Injury

Hypertonic saline 3% is a concentrated sodium chloride solution used in neurocritical care to treat raised intracranial pressure and symptomatic hyponatraemia.

Dosing — no UK product information found

We found no UK product information (SmPC) for this medicine or presentation on the eMC or MHRA Products (checked October 2026). It may be unlicensed in the UK, imported, a medical device, or no longer marketed. ClinCalc Pro shows only doses it can trace to official product information, so none is shown — follow your specialist service or local guideline.

Clinical monograph

How it works

It raises serum osmolality, creating an osmotic gradient that draws water out of brain tissue across an intact blood-brain barrier, reducing cerebral oedema and intracranial pressure.

Prescribing in practice

  • Correct sodium too rapidly and you risk osmotic demyelination syndrome, so monitor serum sodium frequently and limit the rate of rise, particularly in chronic hyponatraemia.
  • Concentrated solutions are an irritant and are best given via central venous access where feasible, with close attention to the infusion site.
  • Use with caution in cardiac failure and volume overload, as the sodium load can precipitate pulmonary oedema.

Monitoring

Monitor serum sodium and osmolality regularly during therapy, alongside fluid balance and neurological status.

Counselling the patient

  • Explain to the team that frequent blood tests are needed to control the speed of sodium correction.
  • Report any new confusion, weakness or swallowing difficulty promptly.

Evidence & guidelines

Hypertonic saline is an established osmotherapy option for raised intracranial pressure and symptomatic hyponatraemia, with use guided by neurocritical care and electrolyte management consensus.

Reference: NICE NG234 TBI; BTF Guidelines 4th Edition; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.